Phibro Animal Health (NASDAQ:PAHC) Shares Gap Down - Should You Sell?

Key Points

• Shares sharply gapped down: PAHC opened at $49.51 after Wednesday's $58.50 close and traded near $45.60 on heavy volume, with the sell‑off largely attributed to investor concern over the company's expanded revolving credit facility.
• Operational beat but neutral guidance: Q3 results topped estimates (EPS $0.76 vs $0.72; revenue $383.5M vs $367.0M), while FY2026 guidance of $2.98–$3.10 EPS essentially brackets consensus (~$3.03), leaving outlook broadly in line with expectations.
• Insider selling and cautious market view: CEO Jack Bendheim sold 58,014 shares (insiders sold ~170,758 shares in the last 90 days) and analysts hold a consensus "Hold" rating with a $42.40 target, reflecting mixed sentiment despite the quarter's beat.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $58.50, but opened at $49.51. Phibro Animal Health shares last traded at $45.5950, with a volume of 121,766 shares changing hands.

Key Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Q3 results beat street estimates — Phibro reported $0.76 EPS vs. $0.72 expected and revenue of $383.5M vs. $367.0M expected; net income and sales rose year‑over‑year, supporting near‑term operational strength. Article Title
• Neutral Sentiment: Updated FY 2026 guidance set EPS at $2.98–$3.10 and revenue about $1.5B — the range brackets the consensus (≈$3.03 EPS), so guidance is essentially in line but not clearly above expectations. Article Title
• Neutral Sentiment: Company declared a small quarterly cash dividend ($0.12 per share, ~0.8% yield) — modest return for income investors but not a material driver of valuation.
• Neutral Sentiment: Launched a companywide sustainable solutions platform (VERRATAIN™) — positive for long‑term ESG positioning but unlikely to move near‑term fundamentals. Article Title
• Negative Sentiment: Expanded revolving credit facility — investors reacted to the move, which may signal increased borrowing needs or elevate concerns about leverage given the company’s existing debt levels; this appears to have been a key catalyst for the sell‑off. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PAHC shares. Citigroup assumed coverage on Phibro Animal Health in a research report on Wednesday, April 15th. They issued a "neutral" rating and a $62.00 price target for the company. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $42.40.

Phibro Animal Health Price Performance

The stock has a market cap of $1.75 billion, a PE ratio of 19.24, a P/E/G ratio of 0.86 and a beta of 0.61. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The business has a 50 day moving average price of $54.07 and a two-hundred day moving average price of $46.48.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.04. The company had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Research analysts expect that Phibro Animal Health Corporation will post 3.03 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 1.1%. Phibro Animal Health's payout ratio is currently 21.33%.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 58,014 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $51.81, for a total transaction of $3,005,705.34. Following the completion of the transaction, the chief executive officer directly owned 64,944 shares of the company's stock, valued at $3,364,748.64. This represents a 47.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 170,758 shares of company stock valued at $8,972,317 in the last 90 days. 50.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. 1620 Investment Advisors Inc. lifted its holdings in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after buying an additional 386 shares in the last quarter. KBC Group NV bought a new stake in Phibro Animal Health during the 1st quarter valued at $29,000. Rothschild Investment LLC lifted its position in shares of Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new stake in shares of Phibro Animal Health during the 3rd quarter valued at $40,000. Institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.